← Back to Search

Behavioural Intervention

Amblyopia therapy with Curesight outside FDA limited ranges for Lazy Eye (ABCDCS Trial)

N/A

Recruiting

Led By Robert W Arnold, MD

Research Sponsored by Alaska Blind Child Discovery

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2-6 months

Awards & highlights

ABCDCS Trial Summary

This trial tests a device to treat amblyopia, a vision problem, in patients at home. Device is used 1.5 hours/day, 6 days/week for 3-6 months to determine if it works.

Who is the study for?

This trial is for individuals with amblyopia, commonly known as 'lazy eye,' who are not part of the Novasight FDA study and have the potential to improve their vision. Participants must have home WiFi access and should not have any neurological or ocular conditions that would prevent visual improvement.Check my eligibility

What is being tested?

The trial is testing a device called Curesight, which patients use at home for 1.5 hours daily, six days a week over 3-6 months. The treatment involves eye-tracking technology aimed at improving visual acuity and stereo vision in people with lazy eye.See study design

What are the potential side effects?

While specific side effects are not detailed here, treatments involving visual exercises typically may cause temporary eyestrain or headaches due to the intensive focus required during sessions.

ABCDCS Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2-6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2-6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2-6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Visual acuity

Secondary outcome measures

stereopsis

ABCDCS Trial Design

1Treatment groups

Experimental Treatment

Group I: Amblyopia therapy with Curesight outside FDA limited rangesExperimental Treatment1 Intervention

Severity of amblyopia and age range outside FDA study

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

CureSight

2018

N/A

~50

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Alaska Blind Child DiscoveryLead Sponsor

9 Previous Clinical Trials

6,202 Total Patients Enrolled

Robert W Arnold, MDPrincipal InvestigatorAlaska Blind Child Discovery

5 Previous Clinical Trials

4,961 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the age eligibility for this research restricted to adults?

"This clinical trial only accepts patients between the ages of 2-20; 22 studies are dedicated to those under 18 and 1 study for participants over 65."

Answered by AI

Are there any additional participants being sought for this experiment?

"Facts published on clinicaltrials.gov indicate that this research project is searching for participants. It was initially advertised on March 1st 2023 and the details were most recently revised December 4th 2023."

Answered by AI

Could I potentially qualify for this research study?

"This clinical trial seeks around 20 individuals with lazy eye aged between two and twenty."

Answered by AI

What is the aggregate sum of participants in this trial?

"Affirmative. Information found on clinicaltrials.gov reveals that this experiment, which was published on March 1st 2023, is actively recruiting participants. To achieve the desired results, a total of 20 individuals must be enrolled from one medical centre."

Answered by AI